Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2019 Filed Jun 21, 2019 19:26 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 3,100 | $77.19 | $239,289.00 |
DisclosureSEC source: 0001127602-19-022529 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 1,294 | $168.41 | $217,920.99 |
DisclosureSEC source: 0001127602-19-021385 · form4.xml · nonDerivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,622 F3 · price: The price of $168.4088 per share represents a weighted average of sales prices ranging from $168.34 to $168.49 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 4,450 | $167.65 | $746,045.17 |
DisclosureSEC source: 0001127602-19-021385 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,916 F2 · price: The price of $167.6506 per share represents a weighted average of sales prices ranging from $167.295 to $168.25 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 4,256 | $166.82 | $710,003.37 |
DisclosureSEC source: 0001127602-19-021385 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,366 F1 · price: The price of $166.8241 per share represents a weighted average of sales prices ranging from $166.29 to $167.27 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 09, 2019 Filed May 13, 2019 16:12 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 306 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-018244 · form4.xml · derivative · entry 2 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on May 9, 2019. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on May 9, 2019. Read SEC document |
| May 09, 2019 Filed May 13, 2019 16:12 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
Exercise / conversionCommon Stock | 306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018244 · form4.xml · nonDerivative · entry 1 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:21 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 500 | $162.20 | $81,100.00 |
DisclosureSEC source: 0001127602-19-017658 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 03, 2019 Filed May 7, 2019 15:00 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,700 | $0.00 Strike: $64.42 | $0.00 |
DisclosureSEC source: 0001127602-19-017528 · form4.xml · derivative · entry 3 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal installments beginning on May 6, 2010 and is now fully exercisable. Read SEC document |
| May 03, 2019 Filed May 7, 2019 15:00 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
SaleCommon Stock | 3,700 | $166.30 | $615,310.00 |
DisclosureSEC source: 0001127602-19-017528 · form4.xml · nonDerivative · entry 2 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,209 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 03, 2019 Filed May 7, 2019 15:00 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
Exercise / conversionCommon Stock | 3,700 | $64.42 | $238,354.00 |
DisclosureSEC source: 0001127602-19-017528 · form4.xml · nonDerivative · entry 1 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 02, 2019 Filed May 6, 2019 12:45 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
SaleCommon Stock | 4,000 | $164.00 | $656,000.00 |
DisclosureSEC source: 0001127602-19-017371 · form4.xml · nonDerivative · entry 1 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,638.0782 Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC |
Ratliff John DCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,787 Underlying: Common Stock · 2,424 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC |
Ratliff John DCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 1,084 | $156.68 | $169,841.12 |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,941 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC |
Ratliff John DCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 2,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:30 UTC |
KING DAVID PDirector · President & CEO
|
Tax withholdingCommon Stock | 41,311 | $154.79 | $6,394,529.69 |
DisclosureSEC source: 0001127602-19-014724 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,386.6004 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:30 UTC |
KING DAVID PDirector · President & CEO
|
GrantCommon Stock | 92,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014724 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,697.6004 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:27 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Tax withholdingCommon Stock | 1,782 | $154.79 | $275,835.78 |
DisclosureSEC source: 0001127602-19-014720 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,656.2468 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:27 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
GrantCommon Stock | 5,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014720 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,438.2468 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:24 UTC |
Dodson Edward TPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 1,779 | $154.79 | $275,371.41 |
DisclosureSEC source: 0001127602-19-014718 · form4.xml · nonDerivative · entry 2 Dodson Edward T · CIK 0001620889 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,662.9335 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:24 UTC |
Dodson Edward TPrincipal Accounting Officer
|
GrantCommon Stock | 5,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014718 · form4.xml · nonDerivative · entry 1 Dodson Edward T · CIK 0001620889 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,441.9335 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:29 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 10,013 | $154.79 | $1,549,912.27 |
DisclosureSEC source: 0001127602-19-014723 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,622 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:29 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantCommon Stock | 22,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014723 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,635 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:20 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Tax withholdingCommon Stock | 3,236 | $154.79 | $500,900.44 |
DisclosureSEC source: 0001127602-19-014710 · form4.xml · nonDerivative · entry 2 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,638.0782 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:20 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
GrantCommon Stock | 7,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014710 · form4.xml · nonDerivative · entry 1 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,874.0782 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:18 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 2,287 | $154.79 | $354,004.73 |
DisclosureSEC source: 0001127602-19-014707 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,999 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:18 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
GrantCommon Stock | 5,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014707 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,286 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:18 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 1,038 | $147.00 | $152,586.00 |
DisclosureSEC source: 0001127602-19-005996 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 F2 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:05 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 11,600 | $0.00 Strike: $146.59 | $0.00 |
DisclosureSEC source: 0001127602-19-005980 · form4.xml · derivative · entry 5 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2029-02-11 F6 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F7 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:05 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005980 · form4.xml · derivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,374 Underlying: Common Stock · 2,820 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:05 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005980 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554 Underlying: Common Stock · 780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:05 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 232 | $146.59 | $34,008.88 |
DisclosureSEC source: 0001127602-19-005980 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,235 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:05 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005980 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC |
Schechter Adam HDirector
|
GrantRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC |
Schechter Adam HDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC |
Schechter Adam HDirector
|
Exercise / conversionCommon Stock | 1,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · derivative · entry 7 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,506 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units vest fully on February 12, 2020. F8 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2020. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. F7 · balance_after: Amount includes 105 Restricted Stock Units that were inadvertently omitted from the reporting person's original Form 4 filed on December 7, 2018, due to a clerical error. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · derivative · entry 6 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F5 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. F7 · balance_after: Amount includes 105 Restricted Stock Units that were inadvertently omitted from the reporting person's original Form 4 filed on December 7, 2018, due to a clerical error. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,700 | $0.00 Strike: $64.42 | $0.00 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · derivative · entry 5 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,700 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 104 | $146.59 | $15,245.36 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · nonDerivative · entry 4 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,013 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 1,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · nonDerivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
SaleCommon Stock | 3,700 | $146.06 | $540,406.83 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,079 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:01 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 3,700 | $64.42 | $238,354.00 |
DisclosureSEC source: 0001127602-19-006034 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:44 UTC |
KING DAVID PDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 52,300 | $0.00 Strike: $146.59 | $0.00 |
DisclosureSEC source: 0001127602-19-006016 · form4.xml · derivative · entry 7 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,300 Underlying: Common Stock · 52,300 shares Expires 2029-02-11 F6 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F7 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:44 UTC |
KING DAVID PDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 12,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006016 · form4.xml · derivative · entry 6 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,957 Underlying: Common Stock · 12,710 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:44 UTC |
KING DAVID PDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006016 · form4.xml · derivative · entry 5 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,247 Underlying: Common Stock · 3,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:44 UTC |
KING DAVID PDirector · President & CEO
|
Tax withholdingCommon Stock | 1,571 | $146.59 | $230,292.89 |
DisclosureSEC source: 0001127602-19-006016 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,280.6004 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:44 UTC |
KING DAVID PDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-006016 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,851.6004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:37 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006012 · form4.xml · derivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Unit vest fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Unit vest fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:37 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006012 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:37 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionCommon Stock | 1,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-006012 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.